| Q92442029 | 2-Deoxy-d-Glucose and Its Analogs: From Diagnostic to Therapeutic Agents |
| Q50253921 | 3-Bromopyruvate antagonizes effects of lactate and pyruvate, synergizes with citrate and exerts novel anti-glioma effects |
| Q41129737 | 3-Bromopyruvate as inhibitor of tumour cell energy metabolism and chemopotentiator of platinum drugs |
| Q34503166 | 3-bromopyruvate enhanced daunorubicin-induced cytotoxicity involved in monocarboxylate transporter 1 in breast cancer cells |
| Q90556178 | 6-Phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 and 4: A pair of valves for fine-tuning of glucose metabolism in human cancer |
| Q28547572 | A Biochemical Approach to Understand the Pathogenesis of Advanced Pulmonary Arterial Hypertension: Metabolomic Profiles of Arginine, Sphingosine-1-Phosphate, and Heme of Human Lung |
| Q52817283 | A Metabolic Therapy for Malignant Glioma Requires a Clinical Measure. |
| Q37163899 | A Novel Agent Enhances the Chemotherapeutic Efficacy of Doxorubicin in MCF-7 Breast Cancer Cells |
| Q90264025 | A Novel Drug Resistance Mechanism: Genetic Loss of Xeroderma Pigmentosum Complementation Group C (XPC) Enhances Glycolysis-Mediated Drug Resistance in DLD-1 Colon Cancer Cells |
| Q61812446 | A Rise in ATP, ROS, and Mitochondrial Content upon Glucose Withdrawal Correlates with a Dysregulated Mitochondria Turnover Mediated by the Activation of the Protein Deacetylase SIRT1 |
| Q39527223 | A combination of 2-deoxy-D-glucose and 6-aminonicotinamide induces oxidative stress mediated selective radiosensitization of malignant cells via mitochondrial dysfunction |
| Q36413261 | A comparative analysis of inhibitors of the glycolysis pathway in breast and ovarian cancer cell line models |
| Q24650249 | A new view of carcinogenesis and an alternative approach to cancer therapy |
| Q42378835 | A novel Fer/FerT targeting compound selectively evokes metabolic stress and necrotic death in malignant cells |
| Q30497799 | A self referencing platinum nanoparticle decorated enzyme-based microbiosensor for real time measurement of physiological glucose transport. |
| Q28477095 | A switching mechanism in doxorubicin bioactivation can be exploited to control doxorubicin toxicity |
| Q27308683 | Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer. |
| Q35017205 | Adenovirus-delivered PDCD5 counteracts adriamycin resistance of osteosarcoma cells through enhancing apoptosis and inhibiting Pgp. |
| Q36063407 | Adverse Cell Culture Conditions Mimicking the Tumor Microenvironment Upregulate ABCG2 to Mediate Multidrug Resistance and a More Malignant Phenotype |
| Q33748081 | Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition |
| Q37158312 | Alpha-tocopheryl succinate induces apoptosis by targeting ubiquinone-binding sites in mitochondrial respiratory complex II. |
| Q37710405 | Altered Mitochondrial Signalling and Metabolism in Cancer |
| Q88208598 | An integrated approach to elucidate signaling pathways of dioscin-induced apoptosis, energy metabolism and differentiation in acute myeloid leukemia |
| Q33689986 | Analyzing the regulation of metabolic pathways in human breast cancer |
| Q39320799 | Anti-proliferation and anti-invasion effects of diosgenin on gastric cancer BGC-823 cells with HIF-1α shRNAs |
| Q36452381 | Anticancer agents that counteract tumor glycolysis. |
| Q39658254 | Assessing p-Glycoprotein (Pgp) Activity In Vivo Utilizing 68Ga–Schiff Base Complexes |
| Q35111997 | Assessment of tumoricidal efficacy and response to treatment with 18F-FDG PET/CT after intraarterial infusion with the antiglycolytic agent 3-bromopyruvate in the VX2 model of liver tumor |
| Q55279249 | B cell lymphoma with different metabolic characteristics show distinct sensitivities to metabolic inhibitors. |
| Q33587154 | Benserazide, a dopadecarboxylase inhibitor, suppresses tumor growth by targeting hexokinase 2. |
| Q33837285 | Berberine Reverses Hypoxia-induced Chemoresistance in Breast Cancer through the Inhibition of AMPK- HIF-1α. |
| Q50561688 | Blocking the utilization of glucose induces the switch from senescence to apoptosis in pseudolaric acid B-treated human lung cancer cells in vitro. |
| Q34154107 | Bromopyruvate mediates autophagy and cardiolipin degradation to monolyso-cardiolipin in GL15 glioblastoma cells. |
| Q53154264 | CXCL12 promotes glycolytic reprogramming in acute myeloid leukemia cells via the CXCR4/mTOR axis. |
| Q36523275 | Can methanolic extract of Nigella sativa seed affect glyco-regulatory enzymes in experimental hepatocellular carcinoma? |
| Q37616057 | Cancer as a metabolic disease: implications for novel therapeutics |
| Q27013632 | Cancer cell metabolism: implications for therapeutic targets |
| Q38728744 | Cancer stem cells, metabolism, and therapeutic significance |
| Q47839039 | Cell death-based treatment of neuroblastoma |
| Q34509607 | Cellular ATP Synthesis Mediated by Type III Sodium-dependent Phosphate Transporter Pit-1 Is Critical to Chondrogenesis |
| Q38782359 | Cellular Glycolysis and The Differential Survival of Lung Fibroblast and Lung Carcinoma Cell Lines |
| Q30276873 | Ceramide-tamoxifen regimen targets bioenergetic elements in acute myelogenous leukemia |
| Q40093371 | Changes in glucose metabolism and gene expression after transfer of anti-angiogenic genes in rat hepatoma. |
| Q35638851 | Chemotherapeutic potential of diazeniumdiolate-based aspirin prodrugs in breast cancer |
| Q91614168 | Citrate-Induced p85α⁻PTEN Complex Formation Causes G2/M Phase Arrest in Human Pharyngeal Squamous Carcinoma Cell Lines |
| Q37129903 | Clinical Response of Metastatic Breast Cancer to Multi-targeted Therapeutic Approach: A Single Case Report |
| Q35946556 | Collateral sensitivity as a strategy against cancer multidrug resistance |
| Q28834339 | Combination delivery of Adjudin and Doxorubicin via integrating drug conjugation and nanocarrier approaches for the treatment of drug-resistant cancer cells |
| Q27317158 | Combined inhibition of glycolysis and AMPK induces synergistic breast cancer cell killing. |
| Q39090765 | Comparative analysis of some aspects of mitochondrial metabolism in differentiated and undifferentiated neuroblastoma cells. |
| Q42032044 | Comparative study of antioxidants as cancer preventives through inhibition of HIF-1 alpha activity |
| Q92636228 | Conformational Studies of Glucose Transporter 1 (GLUT1) as an Anticancer Drug Target |
| Q35032086 | Cryptococcus neoformans requires a functional glycolytic pathway for disease but not persistence in the host |
| Q38446906 | De novo synthesize of bile acids in pulmonary arterial hypertension lung. |
| Q47910184 | Development of GLUT4-selective antagonists for multiple myeloma therapy. |
| Q24652941 | Dichloroacetate (DCA) as a potential metabolic-targeting therapy for cancer |
| Q83600815 | Dichloroacetate restores colorectal cancer chemosensitivity through the p53/miR-149-3p/PDK2-mediated glucose metabolic pathway |
| Q35232780 | Dichloroacetate restores drug sensitivity in paclitaxel-resistant cells by inducing citric acid accumulation |
| Q38924926 | Dichloroacetate, a selective mitochondria-targeting drug for oral squamous cell carcinoma: a metabolic perspective of treatment. |
| Q47239080 | Differential Proteome Analysis of Extracellular Vesicles from Breast Cancer Cell Lines by Chaperone Affinity Enrichment. |
| Q28547207 | Differentiate or Die: 3-Bromopyruvate and Pluripotency in Mouse Embryonic Stem Cells |
| Q43076641 | Direct interaction, instrumental for signaling processes, between LacCer and Lyn in the lipid rafts of neutrophil-like cells. |
| Q92105294 | Diverse Stakeholders of Tumor Metabolism: An Appraisal of the Emerging Approach of Multifaceted Metabolic Targeting by 3-Bromopyruvate |
| Q34468400 | Down-regulation of Ras-related protein Rab 5C-dependent endocytosis and glycolysis in cisplatin-resistant ovarian cancer cell lines |
| Q35899534 | Drug resistance in glioblastoma: a mini review |
| Q39542687 | Dynamic scenario of metabolic pathway adaptation in tumors and therapeutic approach |
| Q50334993 | ENO1 Overexpression in Pancreatic Cancer Patients and Its Clinical and Diagnostic Significance |
| Q92512140 | ENO1 silencing impaires hypoxia-induced gemcitabine chemoresistance associated with redox modulation in pancreatic cancer cells |
| Q36342034 | EPR oxygen imaging and hyperpolarized 13C MRI of pyruvate metabolism as noninvasive biomarkers of tumor treatment response to a glycolysis inhibitor 3-bromopyruvate |
| Q39398652 | Effect of the antitumoral alkylating agent 3-bromopyruvate on mitochondrial respiration: role of mitochondrially bound hexokinase |
| Q36512795 | Effective elimination of cancer stem cells by a novel drug combination strategy |
| Q58077011 | Emerging Potential of Immediate Early Response Gene X-1 in Cardiovascular and Metabolic Diseases |
| Q35052021 | Emerging metabolic targets in cancer therapy |
| Q37137623 | Emerging metabolic targets in the therapy of hematological malignancies |
| Q41471256 | Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer |
| Q36384068 | Establishment of animal model for the analysis of cancer cell metastasis during radiotherapy |
| Q42006639 | Estimation of Pyruvic acid in serum and saliva among healthy and potentially malignant disorder subjects - a stepping stone for cancer screening? |
| Q39398646 | Experimental results using 3-bromopyruvate in mesothelioma: in vitro and in vivo studies |
| Q33971155 | Exploiting mitochondrial dysfunction for effective elimination of imatinib-resistant leukemic cells |
| Q33997798 | Expression of Transketolase like gene 1 (TKTL1) predicts disease-free survival in patients with locally advanced rectal cancer receiving neoadjuvant chemoradiotherapy |
| Q55396364 | Expression of glycolytic enzymes in ovarian cancers and evaluation of the glycolytic pathway as a strategy for ovarian cancer treatment. |
| Q24652381 | Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted |
| Q98386960 | Gene Expression Network Analysis of Precursor Lesions in Familial Pancreatic Cancer |
| Q33425477 | Genomic and oncoproteomic advances in detection and treatment of colorectal cancer |
| Q35560024 | Glucose deprivation in tuberous sclerosis complex-related tumors |
| Q27345982 | Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells |
| Q34591316 | Growth of human gastric cancer cells in nude mice is delayed by a ketogenic diet supplemented with omega-3 fatty acids and medium-chain triglycerides. |
| Q37486782 | Guanylyl cyclase C in colorectal cancer: susceptibility gene and potential therapeutic target |
| Q39951285 | Hacking hexokinase halts tumor growth |
| Q33880100 | Hexokinase II inhibitor, 3-BrPA induced autophagy by stimulating ROS formation in human breast cancer cells |
| Q47112954 | High Dose Parenteral Ascorbate Inhibited Pancreatic Cancer Growth and Metastasis: Mechanisms and a Phase I/IIa study |
| Q34125846 | Hormone Resistance in Two MCF-7 Breast Cancer Cell Lines is Associated with Reduced mTOR Signaling, Decreased Glycolysis, and Increased Sensitivity to Cytotoxic Drugs. |
| Q28543171 | INMAP overexpression inhibits cell proliferation, induces genomic instability and functions through p53/p21 pathways |
| Q42081830 | ITD mutation in FLT3 tyrosine kinase promotes Warburg effect and renders therapeutic sensitivity to glycolytic inhibition |
| Q34489170 | Identification of proteins differentially expressed in adriamycin-resistant (pumc-91/ADM) and parental (pumc-91) human bladder cancer cell lines by proteome analysis |
| Q37708100 | Identification of the metabolic alterations associated with the multidrug resistant phenotype in cancer and their intercellular transfer mediated by extracellular vesicles |
| Q33611455 | Impact of Autoantibodies against Glycolytic Enzymes on Pathogenicity of Autoimmune Retinopathy and Other Autoimmune Disorders |
| Q40293203 | Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs |
| Q46501130 | Impaired mitochondrial functions contribute to 3-bromopyruvate toxicity in primary rat and mouse hepatocytes. |
| Q35666568 | In vitro effect of malachite green on Candida albicans involves multiple pathways and transcriptional regulators UPC2 and STP2. |
| Q30531713 | In vitro optimization of EtNBS-PDT against hypoxic tumor environments with a tiered, high-content, 3D model optical screening platform |
| Q99633688 | In vivo experiments demonstrate the potent antileishmanial efficacy of repurposed suramin in visceral leishmaniasis |
| Q58793684 | Increased glutamine anabolism sensitizes non-small cell lung cancer to gefitinib treatment |
| Q41984797 | Increased glycolytic ATP synthesis is associated with tafenoquine resistance in Leishmania major |
| Q38594681 | Increases in mitochondrial biogenesis impair carcinogenesis at multiple levels |
| Q64079227 | Induction of Apoptosis by a Combination of 2-Deoxyglucose and Metformin in Esophageal Squamous Cell Carcinoma by Targeting Cancer Cell Metabolism |
| Q89487277 | Inhibiting the Activity of NADPH Oxidase in Cancer |
| Q35890367 | Inhibition of Aerobic Glycolysis Attenuates Disease Progression in Polycystic Kidney Disease |
| Q35686894 | Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells |
| Q54978523 | Inhibition of Glycolysis and Glutaminolysis: Emerging Drug Discovery Approach to Combat Cancer. |
| Q39000086 | Inhibition of MAPKs, Myc/Max, NFκB, and hypoxia pathways by Phyllanthus prevents proliferation, metastasis and angiogenesis in human melanoma (MeWo) cancer cell line. |
| Q34104182 | Inhibition of glucose turnover by 3-bromopyruvate counteracts pancreatic cancer stem cell features and sensitizes cells to gemcitabine |
| Q64054569 | Inhibition of glycolysis disrupts cellular antioxidant defense and sensitizes HepG2 cells to doxorubicin treatment |
| Q42127573 | Inhibition of glycolysis modulates prednisolone resistance in acute lymphoblastic leukemia cells |
| Q37071513 | Inhibition of transketolase by oxythiamine altered dynamics of protein signals in pancreatic cancer cells |
| Q35009649 | Intracellular ATP concentration contributes to the cytotoxic and cytoprotective effects of adenosine |
| Q36905125 | Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin |
| Q35740107 | JQ1 suppresses tumor growth through downregulating LDHA in ovarian cancer |
| Q27324380 | Killing hypoxic cell populations in a 3D tumor model with EtNBS-PDT |
| Q36247437 | Knockdown of PKM2 Suppresses Tumor Growth and Invasion in Lung Adenocarcinoma |
| Q61447896 | LDH-A promotes malignant behavior via activation of epithelial-to-mesenchymal transition in lung adenocarcinoma |
| Q38846183 | LMP1 Increases Expression of NADPH Oxidase (NOX) and Its Regulatory Subunit p22 in NP69 Nasopharyngeal Cells and Makes Them Sensitive to a Treatment by a NOX Inhibitor |
| Q35606525 | Lactate dehydrogenase B is associated with the response to neoadjuvant chemotherapy in oral squamous cell carcinoma |
| Q34799147 | Large-scale identification and analysis of suppressive drug interactions |
| Q34173509 | Liverome: a curated database of liver cancer-related gene signatures with self-contained context information |
| Q52730232 | Lkb1 deficiency confers glutamine dependency in polycystic kidney disease. |
| Q91611928 | LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer |
| Q35788743 | Local delivery of cancer-cell glycolytic inhibitors in high-grade glioma |
| Q36489907 | MCT1-mediated transport of a toxic molecule is an effective strategy for targeting glycolytic tumors |
| Q34522318 | MUC1 oncoprotein promotes autophagy in a survival response to glucose deprivation |
| Q52590678 | Management of Glioblastoma Multiforme in a Patient Treated With Ketogenic Metabolic Therapy and Modified Standard of Care: A 24-Month Follow-Up. |
| Q35569305 | Manganese (III) meso-tetrakis N-ethylpyridinium-2-yl porphyrin acts as a pro-oxidant to inhibit electron transport chain proteins, modulate bioenergetics, and enhance the response to chemotherapy in lymphoma cells |
| Q35536092 | Manganese superoxide dismutase: guardian of the powerhouse |
| Q30542280 | Mapping the extracellular and membrane proteome associated with the vasculature and the stroma in the embryo |
| Q35987880 | Mechanisms underlying 3-bromopyruvate-induced cell death in colon cancer |
| Q39265746 | Metabolic Cooperation and Competition in the Tumor Microenvironment: Implications for Therapy. |
| Q37908233 | Metabolic alterations in cancer cells and therapeutic implications |
| Q35213377 | Metabolic alterations in highly tumorigenic glioblastoma cells: preference for hypoxia and high dependency on glycolysis |
| Q47335770 | Metabolic control analysis of cellular respiration in situ in intraoperational samples of human breast cancer |
| Q38968639 | Metabolic effects of hypoxia in colorectal cancer by 13C NMR isotopomer analysis |
| Q53322611 | Metabolic targeting of oncogene MYC by selective activation of the proton-coupled monocarboxylate family of transporters. |
| Q37903736 | Metabolism and brain cancer |
| Q35095550 | Metabolomic heterogeneity of pulmonary arterial hypertension |
| Q38111291 | Mini-review on glycolysis and cancer |
| Q33564338 | Mitaplatin, a potent fusion of cisplatin and the orphan drug dichloroacetate |
| Q36733720 | Mitocans as anti-cancer agents targeting mitochondria: lessons from studies with vitamin E analogues, inhibitors of complex II. |
| Q60930189 | Mitochondrial Substrate-Level Phosphorylation as Energy Source for Glioblastoma: Review and Hypothesis |
| Q98200506 | Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo |
| Q39491915 | Mitochondrial dysfunction and effect of antiglycolytic bromopyruvic acid in GL15 glioblastoma cells. |
| Q37383628 | Mitochondrial dysfunction and reactive oxygen species imbalance promote breast cancer cell motility through a CXCL14-mediated mechanism |
| Q35000248 | Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential |
| Q36006517 | Mitochondrial genome-knockout cells demonstrate a dual mechanism of action for the electron transport complex I inhibitor mycothiazole. |
| Q36119450 | Mitochondrial respiration defects in cancer cells cause activation of Akt survival pathway through a redox-mediated mechanism |
| Q33682181 | Modeling core metabolism in cancer cells: surveying the topology underlying the Warburg effect |
| Q28263577 | Molecular Analysis by Gene Expression of Mitochondrial ATPase Subunits in Papillary Thyroid Cancer: Is ATP5E Transcript a Possible Early Tumor Marker? |
| Q37989980 | Molecular mechanisms of metabolic reprogramming in proliferating cells: implications for T-cell-mediated immunity |
| Q36010195 | Multiple myeloma exhibits novel dependence on GLUT4, GLUT8, and GLUT11: implications for glucose transporter-directed therapy |
| Q34195476 | NMR metabolomic profiling reveals new roles of SUMOylation in DNA damage response |
| Q42181499 | Nanomaterial based self-referencing microbiosensors for cell and tissue physiology research |
| Q47103174 | Non-radioactive 2-deoxy-2-fluoro-D-glucose inhibits glucose uptake in xenograft tumours and sensitizes HeLa cells to doxorubicin in vitro |
| Q28483560 | Novel role of NOX in supporting aerobic glycolysis in cancer cells with mitochondrial dysfunction and as a potential target for cancer therapy |
| Q34116250 | Novel role of p53 in maintaining mitochondrial genetic stability through interaction with DNA Pol gamma |
| Q46859787 | Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy |
| Q35584354 | Optimal control strategies of eradicating invisible glioblastoma cells after conventional surgery. |
| Q26786610 | Ovarian clear cell carcinoma meets metabolism; HNF-1β confers survival benefits through the Warburg effect and ROS reduction |
| Q42535968 | Over-expression of GAPDH in human colorectal carcinoma as a preferred target of 3-bromopyruvate propyl ester |
| Q92713737 | Overcoming chemotherapy resistance via simultaneous drug-efflux circumvention and mitochondrial targeting |
| Q80637346 | Overexpression of transketolase TKTL1 is associated with shorter survival in laryngeal squamous cell carcinomas |
| Q36329780 | Oxidative stress-responsive microRNA-320 regulates glycolysis in diverse biological systems |
| Q27680730 | PFKFB3 Regulates Oxidative Stress Homeostasis via Its S-Glutathionylation in Cancer |
| Q26778007 | Pathophysiological mechanisms of death resistance in colorectal carcinoma |
| Q36351453 | Pharmacologic ascorbate synergizes with gemcitabine in preclinical models of pancreatic cancer |
| Q48464361 | Pharmacologic manipulations of mitochondrial membrane potential (DeltaPsim) selectively in glioma cells |
| Q54968536 | Phosphoglycerate mutase 1 is highly expressed in C6 glioma cells and human astrocytoma. |
| Q36907158 | Preferential killing of human lung cancer cell lines with mitochondrial dysfunction by nonthermal dielectric barrier discharge plasma |
| Q41989445 | Press-pulse: a novel therapeutic strategy for the metabolic management of cancer. |
| Q39445595 | Prognostic significance of glucose transporter-1 (GLUT1) gene expression in rectal cancer after preoperative chemoradiotherapy |
| Q34577887 | Programmed cell death induced by (-)-8,9-dehydroneopeltolide in human promyelocytic leukemia HL-60 cells under energy stress conditions |
| Q36027301 | Proton pump inhibitors for the treatment of cancer in companion animals. |
| Q41186780 | Pyruvic acid levels in serum and saliva: A new course for oral cancer screening? |
| Q28478299 | Quantitative proteomic and interaction network analysis of cisplatin resistance in HeLa cells |
| Q92945136 | Raman-Based in Situ Monitoring of Changes in Molecular Signatures during Mitochondrially Mediated Apoptosis |
| Q24645584 | Redox-directed cancer therapeutics: molecular mechanisms and opportunities |
| Q39910651 | Regression of Dalton's lymphoma in vivo via decline in lactate dehydrogenase and induction of apoptosis by a ruthenium(II)-complex containing 4-carboxy N-ethylbenzamide as ligand. |
| Q36693243 | Regulation of cell proliferation and migration in glioblastoma: new therapeutic approach |
| Q39029569 | Regulation of mitochondrial proliferation by PGC-1α induces cellular apoptosis in musculoskeletal malignancies |
| Q38761736 | Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia. |
| Q36907096 | Resistance to hypoxia-induced necroptosis is conferred by glycolytic pyruvate scavenging of mitochondrial superoxide in colorectal cancer cells. |
| Q40134685 | Reversal of multidrug resistance of adriamycin-resistant gastric adenocarcinoma cells through the up-regulation of DARPP-32. |
| Q37316793 | Role of mitochondria-associated hexokinase II in cancer cell death induced by 3-bromopyruvate |
| Q39907305 | Role of reactive oxygen species-mediated mitochondrial dysregulation in 3-bromopyruvate induced cell death in hepatoma cells : ROS-mediated cell death by 3-BrPA. |
| Q90706093 | Screening and identification of key biomarkers in lung squamous cell carcinoma by bioinformatics analysis |
| Q36633918 | Secrets of the lac operon. Glucose hysteresis as a mechanism in dietary restriction, aging and disease |
| Q39735375 | Selection of endogenous 13C substrates for observation of intracellular metabolism using the dynamic nuclear polarization technique |
| Q36678329 | Sestrin2 integrates Akt and mTOR signaling to protect cells against energetic stress-induced death |
| Q39169792 | Shugoshin1 enhances multidrug resistance of gastric cancer cells by regulating MRP1, Bcl-2, and Bax genes |
| Q33570738 | Silencing VDAC1 Expression by siRNA Inhibits Cancer Cell Proliferation and Tumor Growth In Vivo |
| Q50050739 | Silencing of NADPH oxidase 4 attenuates hypoxia resistance in neuroblastoma cells SHSY-5Y by inhibiting PI3K/Akt-dependent glycolysis |
| Q41084130 | Single-cell time-lapse imaging of intracellular O2 in response to metabolic inhibition and mitochondrial cytochrome-c release |
| Q39606293 | Smad4 inactivation promotes malignancy and drug resistance of colon cancer |
| Q37648872 | Small mitochondria-targeting molecules as anti-cancer agents |
| Q39972485 | Specificity of the anti-glycolytic activity of 3-bromopyruvate confirmed by FDG uptake in a rat model of breast cancer. |
| Q33961565 | Stage-related alterations in renal cell carcinoma--comprehensive quantitative analysis by 2D-DIGE and protein network analysis |
| Q64099481 | Strategies in regulating glioblastoma signaling pathways and anti-invasion therapy |
| Q28477166 | Structure-based development of small molecule PFKFB3 inhibitors: a framework for potential cancer therapeutic agents targeting the Warburg effect |
| Q21195224 | Suppression of adenine nucleotide translocase-2 by vector-based siRNA in human breast cancer cells induces apoptosis and inhibits tumor growth in vitro and in vivo |
| Q41592835 | Suppression of pyruvate dehydrogenase kinase-2 re-sensitizes paclitaxel-resistant human lung cancer cells to paclitaxel |
| Q47707343 | Synthesis and in vitro biological evaluation of thiosulfinate derivatives for the treatment of human multidrug-resistant breast cancer |
| Q38946885 | Systemic delivery of microencapsulated 3-bromopyruvate for the therapy of pancreatic cancer |
| Q38073759 | Systems biology of cancer: moving toward the integrative study of the metabolic alterations in cancer cells. |
| Q34539146 | TP53 mutation hits energy metabolism and increases glycolysis in breast cancer |
| Q34537709 | Tabebuia avellanedae naphthoquinones: activity against methicillin-resistant staphylococcal strains, cytotoxic activity and in vivo dermal irritability analysis |
| Q26783195 | Targeted Therapies in Adult B-Cell Malignancies |
| Q26738876 | Targeting Cancer Metabolism - Revisiting the Warburg Effects |
| Q37983497 | Targeting aerobic glycolysis: 3-bromopyruvate as a promising anticancer drug |
| Q37446828 | Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine |
| Q39418495 | Targeting glycolysis in leukemia: a novel inhibitor 3-BrOP in combination with rapamycin |
| Q89983816 | Targeting metabolic activity in high-risk neuroblastoma through Monocarboxylate Transporter 1 (MCT1) inhibition |
| Q36545721 | Targeting metabolic flexibility by simultaneously inhibiting respiratory complex I and lactate generation retards melanoma progression. |
| Q53776619 | Targeting multidrug-resistant ovarian cancer through estrogen receptor α dependent ATP depletion caused by hyperactivation of the unfolded protein response. |
| Q38925161 | Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin |
| Q33619046 | Tetravalent antibody-scTRAIL fusion proteins with improved properties |
| Q26800604 | The Efficacy of Ketogenic Diet and Associated Hypoglycemia as an Adjuvant Therapy for High-Grade Gliomas: A Review of the Literature |
| Q34580081 | The Warburg effect and its cancer therapeutic implications |
| Q38254050 | The Warburg effect: molecular aspects and therapeutic possibilities |
| Q41986400 | The chemopreventive properties of chlorogenic acid reveal a potential new role for the microsomal glucose-6-phosphate translocase in brain tumor progression |
| Q92354463 | The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells |
| Q39648449 | The combination of the novel glycolysis inhibitor 3-BrOP and rapamycin is effective against neuroblastoma |
| Q38556814 | The effect of 3-bromopyruvate on human colorectal cancer cells is dependent on glucose concentration but not hexokinase II expression |
| Q38695307 | The effect of Nullomer-derived peptides 9R, 9S1R and 124R on the NCI-60 panel and normal cell lines |
| Q36099121 | The energy blockers bromopyruvate and lonidamine lead GL15 glioblastoma cells to death by different p53-dependent routes. |
| Q37461264 | The genome-wide expression profile of 1,2,3,4,6-penta-O-galloyl-β-D-glucose-treated MDA-MB-231 breast cancer cells: molecular target on cancer metabolism |
| Q37358055 | The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. |
| Q38472624 | The influence of mtDNA deletion on lung cancer cells under the conditions of hypoxia and irradiation |
| Q40041752 | The oncoprotein H-RasV12 increases mitochondrial metabolism |
| Q41339597 | The reverse Warburg effect is likely to be an Achilles' heel of cancer that can be exploited for cancer therapy. |
| Q40181421 | The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy. |
| Q37242421 | The role of cellular oxidative stress in regulating glycolysis energy metabolism in hepatoma cells |
| Q42174809 | The role of glucose metabolism and glucose-associated signalling in cancer. |
| Q34591630 | The role of the mitochondrial genome in ageing and carcinogenesis |
| Q26829663 | The three-layer concentric model of glioblastoma: cancer stem cells, microenvironmental regulation, and therapeutic implications |
| Q28391040 | Trailing TRAIL Resistance: Novel Targets for TRAIL Sensitization in Cancer Cells |
| Q64055907 | Tumor Energy Metabolism and Potential of 3-Bromopyruvate as an Inhibitor of Aerobic Glycolysis: Implications in Tumor Treatment |
| Q37337668 | Two-photon autofluorescence dynamics imaging reveals sensitivity of intracellular NADH concentration and conformation to cell physiology at the single-cell level |
| Q37376527 | Upregulation of lactate dehydrogenase a by 14-3-3ζ leads to increased glycolysis critical for breast cancer initiation and progression |
| Q36525103 | ZNF143 transcription factor mediates cell survival through upregulation of the GPX1 activity in the mitochondrial respiratory dysfunction |
| Q55464273 | [Advances in the research of glycolysis and lung cancer]. |
| Q35192732 | miR-290/371-Mbd2-Myc circuit regulates glycolytic metabolism to promote pluripotency |